Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 May 9

PMID 35530846

Authors

Sanjana Reddy

Zineb Barkhane

Jalal Elmadi

Lakshmi Satish Kumar

Lakshmi Sree Pugalenthi

Mahlika Ahmad

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) is defined as an uncontrolled growth of breast cells that affected 2.3 million women in 2020 alone. Until a few years earlier, radiotherapy and chemotherapy were the most commonly used treatments in treating BC; however, many trials and studies were conducted to test the competence of cyclin-dependent kinases 4/6 (CDK4/6) in arresting the cell cycle, and it was found that they were highly influential in halting the disease from progressing. Palbociclib, ribociclib, and abemaciclib are the three drugs that have been approved by the US Food and Drug Administration (FDA) and are even more efficient when used in combination with aromatase inhibitors and fulvestrant. This article aimed to explain the effect of CDK4/6 inhibitors on tumor cells and their efficacy in combination with other drugs. We further explored the development of resistance to these treatments and future possibilities.

References

Hancock S, Tucker M, Hoppe R . Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993; 85(1):25-31. DOI: 10.1093/jnci/85.1.25. View

Wander S, Cohen O, Gong X, Johnson G, Buendia-Buendia J, Lloyd M . The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Discov. 2020; 10(8):1174-1193. PMC: 8815415. DOI: 10.1158/2159-8290.CD-19-1390. View

Bardia A, Hurvitz S, DeMichele A, Clark A, Zelnak A, Yardley D . Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR/HER2 Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clin Cancer Res. 2021; 27(15):4177-4185. PMC: 8487593. DOI: 10.1158/1078-0432.CCR-20-2114. View

Dickler M, Tolaney S, Rugo H, Cortes J, Dieras V, Patt D . MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer. Clin Cancer Res. 2017; 23(17):5218-5224. PMC: 5581697. DOI: 10.1158/1078-0432.CCR-17-0754. View

Vousden K . Regulation of the cell cycle by viral oncoproteins. Semin Cancer Biol. 1995; 6(2):109-16. DOI: 10.1006/scbi.1995.0014. View

Nurse P . A long twentieth century of the cell cycle and beyond. Cell. 2000; 100(1):71-8. DOI: 10.1016/s0092-8674(00)81684-0. View

Turner N, Ro J, Andre F, Loi S, Verma S, Iwata H . Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015; 373(3):209-19. DOI: 10.1056/NEJMoa1505270. View

Kato J, Matsushime H, Hiebert S, Ewen M, Sherr C . Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 1993; 7(3):331-42. DOI: 10.1101/gad.7.3.331. View

Slamon D, Neven P, Chia S, Fasching P, De Laurentiis M, Im S . Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018; 36(24):2465-2472. DOI: 10.1200/JCO.2018.78.9909. View

10.

Murphy C, Dickler M . The Role of CDK4/6 Inhibition in Breast Cancer. Oncologist. 2015; 20(5):483-90. PMC: 4425391. DOI: 10.1634/theoncologist.2014-0443. View

11.

Harper J, Brooks G . The mammalian cell cycle: an overview. Methods Mol Biol. 2004; 296:113-53. DOI: 10.1385/1-59259-857-9:113. View

12.

Jansen V, Bhola N, Bauer J, Formisano L, Lee K, Hutchinson K . Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res. 2017; 77(9):2488-2499. PMC: 5421398. DOI: 10.1158/0008-5472.CAN-16-2653. View

13.

Shah A, Bloomquist E, Tang S, Fu W, Bi Y, Liu Q . FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2018; 24(13):2999-3004. DOI: 10.1158/1078-0432.CCR-17-2369. View

14.

Yuan K, Wang X, Dong H, Min W, Hao H, Yang P . Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. Acta Pharm Sin B. 2021; 11(1):30-54. PMC: 7838032. DOI: 10.1016/j.apsb.2020.05.001. View

15.

Jessen B, Lee L, Koudriakova T, Haines M, Lundgren K, Price S . Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors. J Appl Toxicol. 2007; 27(2):133-42. DOI: 10.1002/jat.1177. View

16.

Mayer E, DeMichele A, Rugo H, Miller K, Waks A, Come S . A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019; 30(9):1514-1520. DOI: 10.1093/annonc/mdz198. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F . Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Front Oncol. 2019; 9:666. PMC: 6664013. DOI: 10.3389/fonc.2019.00666. View

19.

Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M . Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2016; 36(16):2255-2264. PMC: 5393973. DOI: 10.1038/onc.2016.379. View

20.

Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S . Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016; 375(18):1738-1748. DOI: 10.1056/NEJMoa1609709. View